Spineway (ALSPW) Q4 2025 TU earnings summary

Executive summary

• Achieved full-year revenue of €12.4 million in 2025, up 4% year-over-year, driven by strong Q4 sales acceleration and key account orders.

• Q4 2025 revenue rose 34% to €3.8 million compared to Q4 2024, reflecting dynamic market activity.

• Over 75% of revenue is generated from exports, supported by a network of 50+ independent distributors.

Financial highlights

• H1 2025 revenue declined 15% year-over-year to €5.57 million, while H2 2025 revenue increased 27% to €6.86 million.

• Full-year revenue increased 4% to €12.43 million from €11.95 million in 2024.

Outlook and guidance

• Expects new product approvals in 2026 for premium ranges in Latin America and Asia.

• Aims to consolidate market positions and become a major player in spine surgery.